Risk factors for endoscopic ultrasound-guided radiofrequency ablation adverse events in patients with pancreatic neoplasms: a large national French study (RAFPAN study).
Fiche publication
Date publication
avril 2023
Journal
Gastrointestinal endoscopy
Auteurs
Membres identifiés du Cancéropôle Est :
Dr HABERSETZER François, Dr VUITTON Lucine
Tous les auteurs :
Napoléon B, Lisotti A, Caillol F, Gasmi M, Ah-Soune P, Belle A, Charachon A, Cholet F, Eyraud PY, Grandval P, Gonzalez JM, Habersetzer F, Koch S, Le Rhun M, Mangialavori L, Musquer N, Palazzo M, Poincloux L, Privat J, Sportes A, Stouvenot M, Subtil C, Thomassin L, Vanbiervliet G, Vidal G, Vuitton L, Giovannini M, Barthet M
Lien Pubmed
Résumé
Endoscopic ultrasound radiofrequency ablation (EUS-RFA) has been described as a potentially curative option for solid and cystic pancreatic neoplasms. We aimed to assess the safety and efficacy of pancreatic EUS-RFA in a large study population.
Mots clés
IPMN, Insulinoma, Wirsung, endocrine neoplasm, metastasis, pancreatic cancer, radiofrequency ablation
Référence
Gastrointest Endosc. 2023 04 12;: